NASDAQ OMX

Zuora Acquires Leeyo, the Leading Provider of Revenue Recognition Software, to Ease the Burden of Imminent Accounting Standards

Dela

Zuora RevPro will be the most comprehensive ASC 606 and IFRS 15 compliant solution available

SAN MATEO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Zuora, Inc., the leading provider of subscription commerce, billing and finance solutions, today announced that it has signed a definitive agreement to acquire Leeyo Software Inc.®, the undisputed leader in revenue recognition automation. Zuora® will add Leeyo RevPro®, the cloud-based, enterprise-grade ASC 606 and IFRS 15 compliant revenue recognition solution, to its order-to-cash product portfolio. This creates a one-stop shop for automating financial operations, further increasing Zuora's dominance in the $102 billion market for Subscription Economy® tools.

In recent years, many reports have documented the global subscription movement. The Economist found that 80 percent of customers are demanding new consumption models and moving away from traditional ownership. Credit Suisse reported that people in the U.S. spent $420 billion on subscriptions in 2015, up from $215 billion in 2000. Companies like Salesforce.com, Amazon, Netflix, and Box were the early disruptors in the Subscription Economy. However, the story is now far broader and deeper, and relevant to every industry in the world. Companies in media and entertainment, consumer services, telecom and utilities, financial services, healthcare, education, manufacturing and even farming are all pivoting to subscription businesses. According to McKinsey & Company, digital services are expected to account for about three-quarters of global growth over the coming decade.

As mixed business models emerge, the complexities of revenue reporting are forcing financial regulators around the world to change global accounting standards. As a result, beginning in fiscal 2018-2019 companies large and small, public and private, must now adopt the new ASC 606 and IFRS 15 revenue guidelines. This is the biggest change to accounting standards in the last 100 years. According to PwC, more than half of the affected companies - particularly those that bundle subscription and non-subscription services - are unprepared to adopt these new standards.

"We've been saying that accounting standards have to change to accommodate the Subscription Economy, and now they have," said Tien Tzuo, CEO and founder of Zuora. "Every company, regardless of revenue mix, product or service offerings, will be impacted by these new accounting standards. We've partnered with Leeyo for over three years, and today we join forces to help our customers alleviate the burden of dealing with these new standards."

Consistency and comparability of financial reporting across all industries, geographies and business models is beneficial to investors. However, the new standards significantly increase the compliance burden for reporting companies. This will lead to:

  • Hours of additional manual labor for companies who manage these complex calculations with spreadsheets
  • Costly earnings restatements and tarnished reputations for companies who report inaccurately
  • Lengthy audits and potential litigation for companies that don't comply with the guidelines

Reporting becomes increasingly time consuming, labor intensive and risky, wreaking havoc on finance teams if the rules are not adopted accurately and on time. Leeyo's RevPro software automates these critical revenue recognition processes, helping businesses save countless hours, improving investor confidence and building greater stability in public markets.

RevPro has over one hundred customers running an estimated $266 billion annually through its revenue recognition engine. Together, the combined company becomes a one-stop shop for managing customer records, product catalogues, subscriptions, billing, orders, cash, and revenue recognition.

"At Leeyo, we are tremendously proud of the company and market leading product we've built. Being part of Zuora allows us to reach a broader range of companies looking for revenue automation, transparency and consistency in corporate financials," said Jagan Reddy, CEO of Leeyo. "RevPro is a natural fit for Zuora's product portfolio and completes the full order-to-revenue process."

Customer and Analyst Comments

Zendesk VP Global Corporate Controller Christina Liu: "Traditional financial systems and manual processes don't work for the fast paced world of Zendesk. Zuora and Leeyo have been critical to our ability to automate and scale our financial operations. We're excited the two companies are coming together to allow us to have a single-source-of-truth for our order to cash process."

Connor Group CEO Jeff Pickett: "With the latest changes in the accounting standards to globally unify revenue recognition, Zuora's acquisition of Leeyo makes perfect sense. Combining all these capabilities under one roof will significantly help simplify compliance and financial reporting."

MGI Research Managing Director Andrew Dailey: "This is a smart move that unites the best of breed leader in revenue recognition with an Agile Billing leader. It's a win for Leeyo and Zuora customers, and adds breadth and depth to Zuora's play in delivering an Agile Monetization Platform."

SurveyMonkey COO and CFO Tim Maly: "As the world's leading online survey platform with more than 3 million responses every day, SurveyMonkey relies on Leeyo to handle high volume transactions for our self-serve business and Zuora's subscription billing streamlines our high-growth sales supported business. The benefits of both products keep us focused on what matters most, our customers."

Learn more about Zuora and Leeyo at Subscribed on June 5-7, 2017 at the Marriott Marquis in San Francisco. Register here.

Additional Resources
Download the Zuora guide on ASC 606 and IFRS 15 
"The Subscription Economy: A Business Transformation" by Tien Tzuo, CEO of Zuora
SlideShare: "Drivers of Success in the Subscription Economy"
MGI Research Forecast on Agile Monetization Platforms 2016-2020
About RevPro: https://leeyo.com/revpro/revpro-overview/

Follow us online:
Facebook.com/zuora
@Zuora
#SubscriptionEconomy

About Zuora, Inc.
Zuora is a SaaS company and the world's foremost evangelist of the Subscription Economy. Zuora's leading subscription relationship management platform helps enable businesses in any industry to launch or shift products to subscription, implement new pay-as-you-go pricing and packaging models, gain new insights into subscriber behavior, open new revenue streams, and disrupt market segments to gain competitive advantage. Zuora serves more than 800 companies around the world in every industry, including Box, Komatsu, Rogers, Schneider Electric, Toshiba, Xplornet and Zendesk. The Subscription Economy Index (SEI) demonstrates that SEI companies are growing revenues approximately nine times faster than the S&P 500. Headquartered in Silicon Valley, Zuora also operates offices in Atlanta, Boston, Denver, San Francisco, London, Paris, Beijing, Sydney and Tokyo.

About Leeyo Software, Inc.
Leeyo's next-generation revenue recognition software rescues companies and revenue teams of all sizes from the chaos of today's manual data entry or customized processes. Leeyo RevPro - the most complete revenue recognition software suite on the market - automates and manages every process facing a revenue team, seamlessly integrating with the quote-to-cash processes of any ERP system to deliver unparalleled visibility, functionality and configurability to the revenue recognition and reporting process. Learn more about Leeyo and RevPro at: www.leeyo.com

© 2017 Zuora, Inc. All Rights Reserved. Zuora, Subscribed and Subscription Economy are trademarks of Zuora, Inc. Third party trademarks mentioned above are owned by their respective companies. Nothing in this press release should be construed to the contrary, or as an approval, endorsement or sponsorship by any third parties of Zuora, Inc. or any aspect of this press release. To learn more about the Zuora platform, please visit www.zuora.com.

© 2017 Leeyo Software Inc. All Rights Reserved. Leeyo, the Leeyo logo, RevPro, and the RevPro logo are trademarks of Leeyo Software Inc. All other trademarks are property of their respective owners. Learn more about Leeyo and RevPro at: www.leeyo.com

Media Contact:
Jayne Scuncio
jscuncio@zuora.com
408-348-1087




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zuora, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept.  21, 2017  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech

At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58Pressmeddelande

LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service.  As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00Pressmeddelande

Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00Pressmeddelande

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea

Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00Pressmeddelande

Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23Pressmeddelande

DANVERS, Mass., Sept.  20, 2017  (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum